| 000 | 01030 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250513074544.0 | ||
| 264 | 0 | _c19930302 | |
| 008 | 199303s 0 0 eng d | ||
| 022 | _a0894-9255 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarr, A | |
| 245 | 0 | 0 |
_aRoundtable discussion: management issues in didanosine therapy. _h[electronic resource] |
| 260 |
_bJournal of acquired immune deficiency syndromes _c1993 |
||
| 300 |
_aS51-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aDidanosine _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHealth Personnel |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aOccupational Exposure |
| 650 | 0 | 4 |
_aPancreatitis _xchemically induced |
| 650 | 0 | 4 |
_aPeripheral Nervous System Diseases _xchemically induced |
| 650 | 0 | 4 |
_aZidovudine _xtherapeutic use |
| 700 | 1 | _aPenny, R | |
| 773 | 0 |
_tJournal of acquired immune deficiency syndromes _gvol. 6 Suppl 1 _gp. S51-5 |
|
| 999 |
_c8380453 _d8380453 |
||